Samsung Bioepis has now allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.

Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...

Gilead Sciences has announced EMA validation for a parallel accelerated review of lenacapavir’s MAA and EU-M4all applications ...

The EMA has granted approval for an additional 2 mL pre-filled pen option for Takeda’s Takhzyro, aimed at treating HAE.

The FDA has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence application (sBLA) for Opdivo and Yervoy ...

Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling ...

Rather than dampening demand, pharmaceutical supply challenges present opportunities for innovation to transport specialists.

In an anonymous post in the BMJ, the author claims that words relating to DEI could lead to grants being taken away.

With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions are no longer allowed – for now.

Pfizer has signed a deal with Summit Therapeutics to assess the efficacy of Summit’s ivonescimab in combination with several ...

MeiraGTx’s investigational gene therapy AAV-AIPL1 has improved the sight of 11 children who were born blind. MeiraGTx is ...